Moreover, combined treatment with MAPK pathway and HDAC inhibitors suppressed MITF expression and melanoma resistance offering a novel clinical strategy to achieve more durable control of some BRAFV600E melanomas [60]. The gene discussed is HDAC9; the disease is melanoma.